 LexaGene Holdings Inc announced that it has completed the first stage of its agreement with the US Armys Combat Capabilities Development Command DEVCOM, reporting a successful detection of anthrax spores on the MiQLab system. The molecular diagnostic company is working to foster innovative biothreat defense capabilities which fall in line with DEVCOMs current technology priorities. 